Cardiac Biomarkers Market, by Product Type (Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Troponins (T and I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), and Others), by Application (Myocardial Infarction, Cong

Cardiac Biomarkers Market, by Product Type (Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Troponins (T and I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), and Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), by Location of Testing (Laboratory testing and Point of Care Testing), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cardiac biomarkers are substances that are released into the blood when the heart is damaged or stressed. Measurements of these biomarkers are used to help diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. Tests for cardiac biomarkers can also be used to help determine a person’s risk of having these conditions or to help monitor and manage someone with suspected ACS and cardiac ischemia.
It is important to distinguish heart attacks from angina, heart failure, or other conditions that may have similar signs and symptoms because the treatments and monitoring requirements are different. Cardiac biomarker tests are used to detect the presence of ACS and cardiac ischemia and to evaluate their severity. The increase in one or more cardiac biomarkers in blood can identify people with ACS or cardiac ischemia, allowing rapid and accurate diagnosis and appropriate treatment of their condition.
Market Dynamics
Increasing prevalence of cardiovascular diseases and rising awareness in people across the globe is expected to fuel the market growth of cardiac biomarkers over the forecast period. For instance, according to the World Health Organization, in 2019 around 17.9 million deaths were reported globally due to cardiovascular diseases, out of which 85% deaths were caused due to strokes and heart attacks, while 32% of the globally reported deaths were caused due to other diseases, which makes cardiovascular disease as the top cause of death worldwide.
The increasing government initiatives to increase awareness about cardiovascular diseases is expected to drive the growth of global cardiac biomarkers market. For instance, in June 2021, the Australian government made an investment of AUD 29 million (US$ 22 million) under the Medical Research Future Fund’s (MRFF) Cardiovascular Health Mission. This was the first round of investment out of the total AUD 220 million (US$ 167 million) allotted for research in the management of cardiovascular diseases to prevent heart attack and stroke, which are the top most causes of death in Australia.
Key features of the study:
This report provides in-depth analysis of the global cardiac biomarkers market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cardiac biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Randox Laboratories Ltd, Siemens Healthineers, and BioMerieux SA.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The cardiac biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiac biomarkers market
Detailed Segmentation:
Global Cardiac Biomarkers Market, By Product Type:
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobulin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
Global Cardiac Biomarkers Market, By Application:
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
Global Cardiac Biomarkers Market, By Location of Testing:
Laboratory Testing
Point-of-Care Testing
Global Cardiac Biomarkers Market, By Region:
North America
By Product Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
By Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Location Of Testing
Laboratory Testing
Point-of-Care Testing
By Country:
U.S.
Canada
Latin America
By Product Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
By Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Location Of Testing
Laboratory Testing
Point-of-Care Testing
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
By Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Location Of Testing
Laboratory Testing
Point-of-Care Testing
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
By Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Location Of Testing
Laboratory Testing
Point-of-Care Testing
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
By Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Location Of Testing
Laboratory Testing
Point-of-Care Testing
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
By Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Location Of Testing
Laboratory Testing
Point-of-Care Testing
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles :
Abbott Laboratories
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
F. Hoffmann-La Roche AG
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Danaher Corporation
Randox Laboratories Ltd
Siemens Healthineers
BioMérieux SA
“*” marked represents similar segmentation in other categories in the respective section.